SCHEMBL142118

SCHEMBL142118

Cc1ccc(-c2ccc(Nc3ccc(C(=O)N4CCOCC4)cc3)c(C#N)c2)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
TYK2 P29597 1/20 0.47
HPGD P15428 6/20 0.46
JAK2 O60674 1/20 0.46
TBK1 Q9UHD2 1/20 0.46
GAA P10253 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
LRRK2 Q5S007 3/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.44
ATM Q13315 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
BRD4 O60885 1/20 0.43
CREBBP Q92793 1/20 0.43
CHEK1 O14757 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL149035 0.86 TYK2 (0.53) TTKSMN1; SMN2TYK2HPGDJAK2
SCHEMBL13284940 0.85 TTK (0.53) TTKSMN1; SMN2HPGDJAK2GAA
SCHEMBL144961 0.83 TYK2 (0.49) TTKTYK2HPGDJAK2TBK1
SCHEMBL142450 0.82 TYK2 (0.50) SMN1; SMN2TYK2HPGDNPC1LRRK2
SCHEMBL27852018 0.82 TYK2 (0.55) TTKSMN1; SMN2TYK2HPGDJAK2
SCHEMBL141118 0.80 TYK2 (0.55) SMN1; SMN2TYK2HPGDJAK2TBK1
SCHEMBL27833935 0.80 TYK2 (0.55) SMN1; SMN2TYK2HPGDNPC1RXFP1
SCHEMBL141845 0.77 TYK2 (0.48) TYK2HPGDJAK2GAALRRK2
SCHEMBL140875 0.76 EPHX2 (0.57) SMN1; SMN2TYK2HPGDJAK2NPC1
SCHEMBL110138 0.73 ABL1 (0.50) TYK2JAK2GAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 TTK 269/4885SMN1; SMN2 3642/4885TYK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.